tbuckley/cabot-search huggingface dataset:
JOURNALS ABSTRACTED IN THE CURRENT MEDICAL LITERATURE DEPARTMENT, JANUARY-JUNE 1935
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dietary treatment of highly concentrated omega-3 fatty acids increases tumor necrosis factor alpha and reduces antioxidant levels in stable heart transplant recipients Torbjorn Holm, Rolf K. Berge, Arne K. Andreassen, Thor Ueland, John Kjekshus, Svein Simonsen, Lars Gullestad, Paal Aukrust. Rikshospitalet, University of Oslo, Norway
Journal: Journal of the American College of Cardiology (2001)
Physician Payment: Fee for Time
Authors: Francis O. Walker
Journal: JAMA (1994)

<h3>To the Editor.</h3> —In their article on a fee-for-time system, Drs Wachtel and Stein<sup>1</sup>argue for the controversial proposal that physician compensation should be based solely on time. The approach is inherently counterintuitive. Should a talkative dermatologist who sees 20 patients a day be paid the same as a terse one who sees 60? Is 2 hours spent replacing a hip equivalent to four half-hour sessions demonstrating back exercises? Is 1 hour spent doing laparoscopic tubal ligation worth the same as time spent discussing the use of birth control pills? Given such obvious shortcomings of the feefor-time proposal, one wonders how it merits serious consideration. Perhaps the authors were so concerned with pay differences between specialties that they overlooked the adverse effects of a fee-for-time system within specialties. Attempts to define relative value by formula, although new to medicine, are not new to the workplace. Rhoads, in one of
EFICACIA Y SEGURIDAD DE LA RESECCION ENDOSCOPICA MUCOSA EN LA NEOPLASIA ESOFAGICA SUPERFICIAL
Authors: A Belda Cuesta, JM Esteban, J Pérez De La Serna Bueno, L Ortega Medina, A Ruiz De León San Juan, A Sánchez Pernaute, E Rey Díaz-Rubio
Journal: Endoscopy (2013)

Introducción: La Resección Endoscópica Mucosa (REM) ha demostrado su capacidad para establecer el diagnóstico de certeza y para el tratamiento de la neoplasia superficial en Esófago de Barrett (EB). Objetivo: Establecer la eficacia y seguridad de la REM para las lesiones nodulares y para las neoplasias superficiales de esófago. Material y Método: Estudio prospectivo que incluyó 32 pacientes (28 hombres con edad media de 66.39 años) sometidos a un total de 39 procedimientos (REM) de lesiones nodulares sobre EB desde Agosto 2008 – Febrero 2013. Todos los procedimientos se realizaron con endoscopia de alta definición, realizando la mucosectomía con sistema Duette. Resultados: Se realizaron 81 resecciones (REM) en 39 procedimientos, siendo incluidos 32 de ellos dentro del protocolo de tratamiento del Barrett para la resección de lesiones focales. En 14 pacientes la REM se realizó tras tratamiento con radiofrecuencia (RFA) por aparición de lesiones nodulares de novo, y en 3 ocasiones para la resección de carcinoma epidermoide superficial. El estudio histológico mostró carcinoma sobre Barrett estadío T1a, T1b y T2 en 14, 5 y 1 pacientes, respectivamente. Displasia de alto grado (DAG) en 11 casos y displasia de bajo grado (DBG) en 1 caso. Carcinoma epidermoide estadio T1a en 3 casos y junto con zona de DAG en 1 caso. 1 caso se encuentra pendiente del resultado histológico. Observamos 6 episodios de rezumado hemorrágico y un sangrado arterial controlados endoscópicamente. En un caso estenosis con requerimiento de dilataciones neumáticas. En 3 casos se desestimó la cirugía por morbilidad asociada. En 2 casos la pieza quirúrgica no evidenció malignidad y en 1 caso se evidenció pT1N1. Conclusiones: Nuestros resultados avalan la eficacia, seguridad y validez de la REM para el manejo de la neoplasia superficial esofágica si bien se requiere formación y tener previsto el manejo de las complicaciones que puedan aparecer.
Journal of Laryngology and Otology, London
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sarcoidosis and autonomous parathyroid hyperplasia
Authors: R. F. Bohnen
Journal: JAMA (1971)

A patient had corticosteroid-resistant hypercalcemia and nephrocalcinosis caused by sarcoidosis. Investigations suggested autonomous hyperfunction of the parathyroid glands, and at surgery hyperplasia was the only abnormality found, Sarcoidosis and hyperparathyroidism may coexist even in the absence of a parathyroid adenoma.
Cushing's Syndrome Caused by Mediastinal Tumor?
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NECROLOGY.
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Helium Perfusion Technique Advances
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Angiography in Cerebrovascular Disease
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Deaths
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SEWAGE DISPOSAL IN CHICAGO.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Increase in the 8-Hydroxyguanine Repair Activity in the Rat Kidney after the Administration of a Renal Carcinogen, Ferric Nitrilotriacetate
Authors: Raizo Yamaguchi, Takeshi Hirano, Shinya Asami, Atsuo Sugita, Hiroshi Kasai
Journal: Environmental Health Perspectives (1996)

One type of oxidative DNA damage, 8-hydroxyguanine (8-OH-Gua), is known to increase in rat kidney DNA after the administration of a renal carcinogen, ferric nitrilotriacetate (Fe-NTA).To determine the involvement of oxygen radicals in Fe-NTA carcinogenesis, we examined whether the 8-OH-Gua repair enzymes are induced in the rat kidney after Fe-NTA administration, in addition to our analysis of the 8-OH-Gua levels in the DNA, because the 8-OH-Gua repair activity is known to be induced in mammalian cells by oxidative stress due to ionizing radiation.The 8-OH-Gua repair enzyme activity was determined with an endonuclease assay using a 22-mer double strand DNA, which contains 8-OH-Gua at a specific position.A significant increase in the 8-OH-Gua repair activity was observed in the rat kidney after a single intraperitoneal injection of Fe-NTA (p<0.01).This is the first report on the induction of the repair activity for 8-OH-Gua after treatment with a chemical carcinogen.This assay will be useful for evaluating the carcinogenicity of oxygen radical-forming chemicals.
Dietary Therapy in Type II Diabetes Mellitus
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
STM-01: Phase I EFFTox study of aurora A kinase inhibitor alisertib (MLN8237) given in combination with selective VEGFR inhibitor pazopanib for therapy of solid tumors.
Authors: Arkadiusz Z. Dudek, Imran Unal, Hui Xie, Lawrence Eric Feldman, Neeta K. Venepalli, Oana Cristina Danciu
Journal: Journal of Clinical Oncology (2015)

TPS2610 Background: Pazopanib is a potent and selective multi-targeted tyrosine kinase inhibitor targeting VEGF, PDGF and C-KIT and inhibits angiogenesis and tumor growth. Alisertib is a highly selective small molecule inhibitor of Aurora A kinase which may result in disruption of the assembly of the mitotic spindle apparatus and cell proliferation inhibition. At highest non-toxic concentrations, mitosis targeting agents may reduce endothelial activity and consequently, exhibit antiangiogenic activity. By this way they can enhance the antiangiogenic effects of VEGF inhibitors as well as complement anti-tumor activity, making combination therapy clinically useful to treat advanced refractory malignancies. Methods: This is a Phase I dose escalation study with a modified toxicity probability interval design to evaluate activity and safety of alisertib when given in combination with pazopanib to patient with advanced, previously treated solid tumors and hematologic malignancies. The primary objectives of this study are to determine the optimal tolerated dose, safety and toxicity. Secondary objectives are to establish PK/PD and preliminary antitumor activity. Inclusion Criteria: ECOG PS 0-2, good organ function and a rest period of 2-6 weeks fromprior systemic chemotherapy, immunotherapy, or biological therapy. Administration and Design: Alisertib is taken orally, twice a day for the first 7 days of a 21-day cycle. Pazopanib is taken orally, once a day, continuously. Since study opened in July 2013, 26 patients have been enrolled, so far 16 of them have been on treatment. Study is continuing accrual at dose of alisertib 30 mg twice a day for 7 days and pazopanib 600 mg daily for 21 days. Clinical trial information: NCT01639911.
<i>BRCA1/2</i> Status May Predict Prognosis
Journal: Cancer Discovery (2013)

Abstract A large Dutch study of BRCA1/2 status among younger women diagnosed with breast cancer found that those with a BRCA1 mutation were 1.2 times more likely to die from breast cancer than patients without a BRCA1 mutation. No statistically significant survival difference was found for those with BRCA2 mutations.
SURVEY OF LITERATURE
Journal: British Journal of Dermatology (1942)

British Journal of DermatologyVolume 54, Issue 5 p. 157-158 SURVEY OF LITERATURE First published: May 1942 https://doi.org/10.1111/j.1365-2133.1942.tb10638.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Volume54, Issue5May 1942Pages 157-158 RelatedInformation
ASSOCIATION NEWS.
Authors: Joseph Hoffman
Journal: JAMA (1889)

<h3>Section of Obstetrics and Diseases of Women.</h3> The officers of the Section of Obstetrics and Diseases of Women respectfully request those who desire to read papers in that Section at the meeting of the American Medical Association to be held in Nashville, Tenn., May 20-23, to communicate the titles thereof to either of the undersigned not later than January 15, 1890.
Correction: On the mechanism of anti-CD39 immune checkpoint therapy
Authors: Sara Bedrose, Kevin Charles Miller, Lina Altameemi, Mohamed S Ali, Sameh Nassar, Naveen Garg, Marilyne Daher, Keith D Eaton, Jeffrey Thomas Yorio, Davey B Daniel, Keith C Bible, Ashish V Chintakuntlawar, Mouhammed Amir Habra
Journal: Journal for ImmunoTherapy of Cancer (2020)
Book Review A Primer for Diabetic Patients . By Russell M. Wilder, M.D., Professor and Chairman of the Department of Medicine, University of Chicago Clinics; Formerly Head of the Section on Nutrition, Division of Medicine, Mayo Clinic. Fourth Edition, Revised. 138 pages. Philadelphia and London; W. B. Saunders Company, 1930. Cloth, $1.50.
Journal: New England Journal of Medicine (1931)
Abstract 1211: Hif-1α In T Cells Pathway Plays A Crucial Role In The Progression Of Arteriosclerosis And Artery Intimal Thickening
Authors: Hirotsugu Kurobe, Masahisa Urata, Yuki Izawa, Yayoi Fukuhara, Tamotsu Kanbara, Kenichi Aihara, Masashi Akaike, Frank Gonzalez, Toshio Matsumoto, Toshiaki Tamaki, Tetsuya Kitagawa, Masanori Yoshizumi, Shuhei Tomita
Journal: Circulation (2007)

Background and Objective T cell-mediated inflammatory process is involved in arteriosclerosis and vascular remodeling. Hypoxia-inducible factor-1 (HIF-1) is a transcription factor and regulates the gene expressions in response to hypoxia in order to maintain physiological oxygen homeostasis. In the previous annual meeting, we showed that arterial cuff injury caused prominent neointimal and adventitial hyperplasia in Hif-1α-deficient mice compared to that of the control mice. The object of the present study is to reveal how the function of HIF-1α in T cells contributes to the vascular remodeling. Methods and Results T cell-specific Hif-1α-deficient mice were generated using a Cre-LoxP technology. Vascular remodeling was characterized 4 weeks after femoral arterial injury induced by an external vascular polyethylene cuff model. Morphological and histological studies showed that the cuff placement caused prominent neointimal and adventitial hyperplasia in Hif-1α-deficient mice compared to that of the control mice, and that infiltration of mononuclear cells at the adventitia was remarkably increased in the mutant mice. Hif-1α-deficient T cells were normally generated in the thymus and their distribution in the spleen and lymph nodes was unimpaired. However, number of peripheral Hif-1α-deficient T cells was significantly increased compared to the control. In the in vitro culture condition, Hif-1α-deficient T cells exhibited significant more increases of IL2 production and proliferation upon stimulation with anti-CD3/anti-CD28 antibodies compared to the controls. In addition, productions of 2,4,6-trinitrophenol (TNP)-KLH antigen-specific antibodies, including IgG1, IgG2b and IgG2c, were more enhanced in the mutant mice after stimulation of the antigen. Conclusions HIF-1α in T cells plays a crucial role in vascular inflammation and remodeling in response to cuff injury, serving as a negative regulator of T cell-mediated immune response.